Tralokinumab

Tralokinumab is a monoclonal antibody that is used to treat asthma in adults and adolescents aged 12 years and older. It is an interleukin-13 (IL-13) inhibitor, which means that it works by blocking the action of a certain protein in the body that can make asthma worse. Tralokinumab is administered through subcutaneous injections, usually twice a month. Common side effects of Tralokinumab include injection site reactions, pneumonia, and upper respiratory tract infections.

Tralokinumab is a medication used to treat a specific inflammatory skin condition called moderate to severe eczema. Here's a breakdown of its key points:

How it Works:

• Tralokinumab belongs to a class of drugs called interleukin-13 (IL-13) inhibitors.
• Eczema is caused by an overactive immune system response, and IL-13 is a protein that plays a role in this excessive inflammation.
• Tralokinumab works by specifically blocking IL-13, thereby helping to reduce inflammation and improve eczema symptoms.

Dosage and Administration:

• Tralokinumab is administered as a subcutaneous injection (under the skin) by a healthcare professional, typically once every two weeks.

Effectiveness:

• Tralokinumab can be effective in reducing eczema symptoms like itching, redness, swelling, and scaling of the skin.
• It can significantly improve a patient's quality of life.

Side Effects:

• Common side effects of Tralokinumab can include:
  • Injection site reactions like pain, redness, or swelling.
  • Upper respiratory tract infections (colds, sinus infections)
  • Headache